Skip to main content

Market Overview

Goldman Sachs Maintains Neutral on Hospira

Share:

Goldman Sachs is out with its report today on Hospira (NYSE: HSP), maintaining Neutral.

In a note to clients, Goldman Sachs writes, "Shifting to the long term, we think the company needs to bridge the gap between the slowing sales from Paragraph IV challenge drugs (2012) and the eventual impact from Biosimilars (2014+). International growth could be that bridge, but there is little clarity on this opportunity right now. Continuing to improve margins through efficiencies and boosting ROIC through more efficient use of capital will also be key factors in EPS growth and P/E multiple expansion, in our view. We see room for potential upside on these factors but await greater visibility. At current levels, we see the risk/reward as fairly balanced and maintain our Neutral rating."

Goldman Sachs maintains a $60 PT on HSP.

Shares of HSP closed Monday at $53.07, down 1.15% from Friday's close.

 

Related Articles (HSP)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs HospiraAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com